Sorachai Nitayaphan

发表

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees

Chris Bailey-Kellogg, Jaranit Kaewkungwal, Todd J. Suscovich, 2015, PLoS Comput. Biol..

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial

Raphael Gottardo, Tomer Hertz, Sergei L. Kosakovsky Pond, 2015, PLoS Comput. Biol..

Factors influencing estimates of HIV-1 infection timing using BEAST

Lydia Bonar, Morgane Rolland, Merlin L. Robb, 2021, PLoS Comput. Biol..

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

Gary J. Nabel, Youyi Fong, Peter B. Gilbert, 2014, PloS one.

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

Punnee Pitisuttithum, Sorachai Nitayaphan, Victoria Polonis, 2004, The Journal of infectious diseases.

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Jaranit Kaewkungwal, Joseph Chiu, Nelson L Michael, 2012, The Lancet. Infectious diseases.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Guido Ferrari, Youyi Fong, Jaranit Kaewkungwal, 2012, The New England journal of medicine.

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

Hasan Ahmed, Hongmei Gao, Jaranit Kaewkungwal, 2012, The Journal of infectious diseases.

COMPASS identifies T-cell subsets correlated with clinical outcomes

Greg Finak, Raphael Gottardo, Jaranit Kaewkungwal, 2015, Nature Biotechnology.

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

Jaranit Kaewkungwal, Nelson L Michael, Supachai Rerks-Ngarm, 2012, The Journal of Immunology.

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

Raphael Gottardo, S. Gnanakaran, Hongmei Gao, 2013, PloS one.

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

Gary J. Nabel, Guido Ferrari, Youyi Fong, 2014, Science Translational Medicine.

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2

Tomer Hertz, Peter D. Kwong, Hasan Ahmed, 2012, Nature.

Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial

Raphael Gottardo, Tomer Hertz, John Sidney, 2014, Journal of Virology.

Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Guido Ferrari, Jaranit Kaewkungwal, Xiaozhi Lu, 2013, Immunity.